New Drugs in Non-Small Cell Lung Cancer

Anderson I. , Supko J. , Eder J. , Vasconcelles M. , Shapiro G. , Skarin A. , Shipp M. , Janicek M. , Lynch C. , Lopez M. , Bowers M. , Rasmussen H. : Pilot pharmacokinetic study of Marimastat (MAR) in combination with carboplatin (C)/paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 18: 187a, 1999 (abstr. 719).

Baldini E. , Ardizzoni A. , Cafferata M.A. : Combined gemcitabine, ifosfamide and vinorelbine (GIN): activity and safety of a non-platinum-based regimen in advanced non-small-cell lung cancer (NSCLC). Eur. J. Cancer, 35(Suppl. 4): S264, 1999 (abstr. 1054).

Baselga J. , Herbst R. , LoRusso P. , Rischin D. , Ranson M. , Plummer R. , Raymond E. , Maddox A.M. , Kaye S.B. , Kieback D.G. , Harris A. , Ochs J. : Continuous administration of ZD 1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGF-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol., 19: 177a, 2000 (abstr. 686).

Boni C. , Bisagni G. , Savoldi L. , Franciosi V. , Pezzola A. , De Pas T. : Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of stage IIIB-IV non-small-cell lung cancer. A phase II study of the Italian Oncology Group for Clinical Cancer Research. Proc. Am. Soc. Clin. Oncol., 17: 478a, 1998 (abstr. 1839).

Bonomi P. , Kim K. , Fairclough D. , Kugler J. , Rowinsky E. , Jiroutek M. , Johnson D. : Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin. Results of an Eastern Cooperative Oncology Group Trial. J. Clin. Oncol., 18: 623–631, 2000.

Cartei G. , Sacco C. , Sibau A. , Tumolo S. , Caffo O. , Lucenti A. , De Pangher V.M. , Vigevani E. , Iop A. , RosaBlan A. , Bearz A. , Gusella M. , Segati R. , Tabaro G. : Gemcitabine, ifosfamide and platin in non-small-cell lung cancer (NSCLC): an intention-to-treat phase II “EOLO'’ study. Proc. Am. Soc. Clin. Oncol., 18: 498a, 1999 (abstr. 1923).

Cornelia P. , Frasci G. , De Cataldis G. , Panza N. , Cioffi R. , Curcio C. , Belli M. , Bianco A. , Ianniello G. , Maiorino L. , Della Vittoria M. , Perchard J. , Cornelia G. : Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small cell lung cancer. A multicentre randomised trial. Br. J. Cancer, 74: 1805–1811, 1996.

Diez M. , Pollan M. , Maestro M. , Visvikis A. , Antoniou F. , Kalantaridou A. , Karvounis N. , Batzios S. , Athanassiou A. : Prediction of recurrence by quantification of p185neu protein in non-small cell lung cancer tissue. Br. J. Cancer, 75: 684–689, 1997.

Divgi C.R. , Welt S. , Kris M. , Real F.X. , Yeh S.D. , Gralla R. , Merchant B. , Schweighart S. , Unger M. , Larson S.M. : Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell carcinoma. J. Natl. Cancer Inst., 83: 97–104, 1991.

Gatzemeir U. , von Pawel J. , Gottfried M. , ten Velde G.P.M. , Mattson K. , DeMarinis F. , Harper P. , Salvati F. , Robinet G. , Lucenti A. , Bogaerts J. , Winograd B. , Gallant G. : Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 454a, 1998 (abstr. 1748).

Georgoulias V. , Papadakis E. , Alexopoulos A. , Stavrinidis E. , Bania E. , Rapti A. , Grigoratou T. , Kouroussis C. , Kakolyris S. , Samonis G. : Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small-cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. Proc. Am. Soc. Clin. Oncol., 18: 461a, 1999 (abstr. 1778).

Grilli R. , Oxman A.D. , Julian J.A. : Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J. Clin. Oncol., 11: 1866–1872, 1993.

Herbst R.S. , Tran H.T. , Madden T.L. , Khuri F.R. , Meyers C.A. , Shin D.M. , Puduvalli V.K. , Blumenschein G.R. , Hinton L. , Lee J.S. , Fossella F.V. , Pisters K.M. , Zinner R.G. , Terry K.A. : Phase I study of the angiogenesis inhibitor TNP-470 (T) in combination with paclitaxel (P) in patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 19: 182a, 2000 (abstr. 707).

Kalidas M. , Hammond L.A. , Patnaik A. , Denis L.J. , Hidalgo M. , Schwartz G. , Stephenson J.J. , Felton S.A. , Hao D. , McCreery H. , Williams J. , Holroyd K. , Mamum K. , Eckhardt S.G. , Von Hoff D.D. , Rowinsky E.K. : A phase I and pharmacokinetics (PK) study of the angiogenesis inhibitor, squalamine lactate (MSI-1256F) Proc. Am. Soc. Clin. Oncol., 19: 180a, 2000 (abstr. 698).

Kelly K. , Crowley J. , Bunn P.A. , Livingston R.B. , Gandara D.R. : A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial. Proc. Ami Soc. Clin. Oncol., 18: 461a, 1999 (abstr. 1777).

Kosmidis P.A. , Bacoyiannis C. , Mylonakis N. , Demopoulos M.A. , Dimitriadis K. , Kalofonos H.P. , Samantas E. , Skarlos D. , Fountzilas G. , Tsavdaridis D. , Papakostas P. , Pavlakis G. , Pavlidis N. , Hellenic Cooperative Oncology Group (HeCOG): A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol., 19: 488a, 2000 (abstr. 1908).

Manegold C. , Gatzemeier U. , von Pawel J. , Pirker R. , Malayeri R. , Blatter J. , Krejcy K. : Front-line treatment of advanced non-small cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann. Oncol., 11: 435–440, 2000.

Masuda N. , Fukuoka M. , Negoro S. , Takada Y. , Sugiura T. , Ohashi Y. , Ariyoshi Y. , Niitani H. , and The CPT-11 Lung Cancer Study Group West: Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC). A multicenter phase III study. Proc. Am. Soc. Clin. Oncol., 18: 459a, 1999 (abstr. 1774).

Mattson K. , Saarinen A. , Jekunen A. : Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small-cell lung cancer. Semin. Oncol., 24(Suppl. 14): 5–8, 1997.

Non-small Cell Lung Cancer Cooperative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patient data from 52 randomised clinical trials. BMJ, 311: 899–909; 1995.

Pectasides D. , Aspropotamitis A. , Halikia A. , Visvikis A. , Antoniou F. , Kalantaridou A. , Karvounis N. , Batzios S. , Athanassiou A. : Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 17: 3816–3821, 1999.

Ranson M. , Davidson N. , Nicolson M. , Falk S. , Carmichael J. , Lopez P. , Anderson H. , Gustafson N. , Jeynes A. , Gallant G. , Washington T. , Thatcher N. : Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 92: 1074–1080, 2000.

Recchia F. , De Filippis S. , Saggio G. , Guerriero G. , Rosselli M. , Amiconi G. , Rea S. : Phase II study of gemcitabine, ifosfamide and vinorelbine in advanced non-small-cell lung cancer: activity and toxicity of a platinum-free regimen. Proc. Am. Soc. Clin. Oncol., 18: 489a, 1999 (abstr. 1886).

Sandler A.B. , Nemunaitis J. , Denham C. , von Pawel J. , Cormier Y. , Gatzemeier U. , Mattson K. , Manegold C. , Palmer M.C. , Gregor A. , Nguyen B. , Niyikiza C. , Einhorn L.H. : Phase III trial of gemcitabine plus cisplatin versus cis-platin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 18: 122–130, 2000.

Schiller J.H. , Harrington D. , Sandler A. , Belani C. , Langer C. , Krook J. , Johnson D.H. , Eastern Cooperative Oncology Group: A randomized phase III trial of four chemotherapy regimens in advanced non-small cell ling cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 19: 1a, 2000 (abstr. 2).

Shepherd F.A. , Dancey J. , Ramlau R. , Mattson K. , Gralla R. , O'Rourke M. , Levitan N. , Gressot L. , Vincent M. , Burkes R. , Coughlin S. , Kim Y. , Berille J. : Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol., 18: 2095–2103, 2000.

Sørensen J.B. , Stengygaard L.E. , Dombernowsky P. , Hansen H.H. : Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer. Ann. Oncol., 10: 1043–1049, 1999.

Souquet P.J. , Chauvin F. , Boissel J.P. , Cellerino R. , Cormier Y. , Ganz P.A. , Kaasa S. , Pater J.L. , Quoix E. , Rapp E. : Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet, 342: 19–21, 1993.

Stopeck A. : Results of a dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol., 19: 206a, 2000 (abstr. 802).

Takeda K. , Yamamoto N. , Negoro S. , Nakagawa K. , Matsui K. , Kawahara M. , Takada Y. , Fukuoka M. , Ariyoshi Y. , for the West Japan Thoracic Oncology Group (WJTOG): Randomized phase II study of docetaxel (DOC) plus cisplatin versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLC): A West Japan Thoracic Oncology Group (WJTOG) study. Proc. Am. Soc. Clin. Oncol., 19: 497a, 2000 (abstr. 1944).

Thompson D.S. , Hainsworth J.D. , Scullin D.C. , Kalman L.A. , Butts J.A. , Urba W. , Morrissey L.H. , Burris H.A. , Greco F.A. : Paclitaxel-carboplatin alone or with gemcitabine or vinorelbine for stage IV and IIIB non-small-cell lung cancer: Long-term follow-up. Proc. Am. Soc. Clin. Oncol., 19: 503a (abstr. 1967), 2000.

Tolcher A. , Rowinsky E.K. , Rizzo J. , Britten C. , Siu L. , Humphrey R. , Smetzer L. , Sorenson M. , Von Hoff D.D. , Eckhardt S.G. : A phase I and pharmacokinetics study of the oral matrix metallo-proteinase inhibitor Bay 12–9566 in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol., 18: 160a, 1999 (abstr. 617).

Tsai C. , Chang K. , Perng R. , Mitsudomi T. , Chen M.H. , Kadoyama C. , Gazdar A.F. : Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst., 85: 897–901, 1993.

von Pawel J. , von Roemeling R. , Gatzemeier U. , Boyer M. , Elisson L.O. , Clark P. , Talbot D. , Rey A. , Butler T.W. , Hirsh V. , Olver I. , Bergman B. , Ayoub J. , Richardson G. , Dunlop D. , Arcenas A. , Vescio R. , Viallet J. , Treat J. : Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer. A report of the International CATAPULT I study group. J. Clin. Oncol., 18: 1351–1359, 2000.

Wozniak A.J. , Crowley J.J. , Balcezark S.P. , Weiss G.R. , Spiridonidis C.H. , Baker L.H. , Albain K.S. , Kelly K. , Taylor S.A. , Gandara D.R. , Livingston R.B. : Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group study. J. Clin. Oncol., 16: 2459–2465, 1998.

Yoshimori K. , Yano T. , Yoneda S. , Kuba M. , Ichinose Y. , Kudoh S. , Niitani H. for the Japan UFT Lung Cancer Study Group: A phase II trial of oral UFT and cisplatin inpatients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 469a, 1998 (abstr. 1803).